Investor Presentaiton
Research & Development
Cumulative R&D Spend of Rs 70 billion to date
R&D Spend
•
.
Capabilities
•
R&D spend at 7.2% of Net Sales for FY15*
Strong cash flows & large scale to support R&D investments
Strong research teams in generics, finished dosage development,
biological support, chemistry
Organization
IPR Support
• 2,000 scientists globally with capabilities across dosage forms like
orals, liquids, ointments, gels, sprays, injectables
• Strong team of intellectual property experts supporting R&D
(internal and external lawyers)
Focus
* FY15 numbers include the impact of Ranbaxy merger
© Sun Pharmaceutical Industries Limited. All Rights Reserved.
• Developing non infringing formulations and development of
specialty/complex products
SUN
PHARMA
36View entire presentation